GlassScriptPhysician profile
Kevin Schrand
NPI 1972865350
$3,087.44
in general payments reported to CMS, 2019-2025
12 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Trauma Surgery provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $990 · 2022: $241 · 2023: $505 · 2024: $742 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $893.02 | 2021-2023 | Da Vinci Surgical System |
| Abbott Laboratories | $867.26 | 2021-2025 | Esprit, Jeti |
| Smith+Nephew, INC. | $539.62 | 2023-2025 | Stravix, Oasis, Grafix |
| W. L. Gore & Associates, INC. | $292.08 | 2019-2024 | Gore Synecor Biomaterial |
| Kerecis Limited | $213.88 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $84.35 | 2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Tela Bio, INC. | $58.64 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Takeda Pharmaceuticals U.S.A., INC. | $49.61 | 2023-2024 | Gattex |
| Solventum Corporation | $36.68 | 2025 | Activ.A.C. |
| Royal Biologics, INC. | $18.48 | 2025 | |
| Reprise Biomedical, INC. | $17.06 | 2025 | Miro3d |
| Lilly USA, LLC | $16.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.